Forest Services
In 2024, Aurobindo Pharma, a leading Indian pharmaceutical company, secured the Notice of Compliance (NOC) from Health Canada for its cancer biosimilar. This regulatory approval permits Aurobindo to market its biosimilar oncology drug in Canada, a market valued at approximately USD 2.5 billion (IQVIA, 2023). The milestone highlights India’s advancing capabilities in biopharmaceutical innovation, manufacturing standards, and regulatory compliance, positioning it as a competitive player in the global biosimilars market.
The approval also underscores the strategic importance of biosimilars in reducing cancer treatment costs globally and in India, where affordability remains a challenge. However, India’s domestic regulatory and policy framework for biosimilars remains fragmented, limiting the full potential of such innovations for public health benefit.
UPSC Relevance
- GS Paper 2: Health Sector Policies, Regulatory Frameworks, Intellectual Property Rights
- GS Paper 3: Biotechnology, Economic Impact of Pharmaceutical Innovation, Export Competitiveness
- Essay: Role of Biotechnology in Affordable Healthcare
Regulatory Framework Governing Biosimilars in India and Canada
India’s biosimilar approval process is primarily governed by the Drugs and Cosmetics Act, 1940 (amended 2020) and the New Drugs and Clinical Trials Rules, 2019. Sections 3 and 4 of these rules specifically address biosimilar approvals, requiring demonstration of similarity in safety, efficacy, and quality to the reference biologic. The Central Drugs Standard Control Organization (CDSCO) is the national regulatory authority overseeing these processes.
In Canada, the Food and Drugs Act, R.S.C., 1985, c. F-27 empowers Health Canada to regulate drug safety and efficacy. Health Canada’s NOC signifies that a drug meets Canadian standards for quality, safety, and efficacy, enabling market entry. The approval of Aurobindo’s biosimilar by Health Canada indicates compliance with stringent international regulatory norms.
- The Patents Act, 1970, particularly Section 3(d), restricts patentability of new forms of known substances unless they show enhanced efficacy, impacting biosimilar market entry by limiting evergreening patents (Novartis AG v. Union of India, 2013).
- India’s fragmented biosimilar regulatory framework contrasts with Canada’s centralized system, affecting approval timelines and market access.
Economic Dimensions of Biosimilar Market Growth
The global biosimilars market was valued at approximately USD 17.5 billion in 2023 and is projected to reach USD 61 billion by 2030, growing at a CAGR of around 20% (Grand View Research, 2024). India’s biosimilar sector is expected to grow at 15-18% CAGR, contributing over USD 3 billion by 2025 (Indian Pharmaceutical Alliance, 2023).
Aurobindo’s Health Canada NOC opens access to Canada’s oncology biosimilar market, estimated at USD 2.5 billion (IQVIA, 2023). Indian biosimilar exports increased by 25% in FY 2023-24, with Canada as a key destination. Biosimilars reduce oncology treatment costs by up to 30% compared to originator biologics (WHO, 2023), enhancing affordability.
- The Government of India allocated INR 6,000 crore under the Department of Biotechnology’s Biopharma Mission (2021-2026) to boost biopharmaceutical R&D.
- Cost savings from biosimilars can significantly reduce out-of-pocket expenditure for cancer patients.
Comparison of Biosimilar Regulatory Approaches: India, Canada, and the European Union
| Aspect | India | Canada | European Union (EU) |
|---|---|---|---|
| Regulatory Authority | CDSCO | Health Canada | European Medicines Agency (EMA) |
| Approval Framework | New Drugs and Clinical Trials Rules, 2019; fragmented state-level oversight | Food and Drugs Act, 1985; centralized | Centralized biosimilar approval since 2005 |
| Number of Biosimilars Approved (since 2015) | Limited; approvals mostly domestic | Moderate; growing approvals | 60+ biosimilars approved |
| Market Impact | Slow uptake; fragmented market penetration | Growing market access; stringent standards | 40% reduction in biologic drug costs across member states by 2023 |
| Patent Regime Impact | Section 3(d) restricts evergreening; patent challenges common | Standard patent laws; biosimilars face patent expiry | Robust patent framework; biosimilars encouraged post-patent expiry |
Challenges in India’s Biosimilar Ecosystem
India lacks a centralized, dedicated biosimilar regulatory framework equivalent to the EMA, resulting in inconsistent approval timelines and standards. This fragmentation delays market entry and reduces investor confidence.
Domestic reimbursement policies for biosimilars are underdeveloped, limiting insurance coverage and public procurement. Low public and physician awareness about biosimilars further restricts uptake despite demonstrated cost advantages.
- Inadequate post-marketing surveillance mechanisms hinder long-term safety data collection.
- Patent litigation under Section 3(d) creates uncertainty for biosimilar developers.
- Limited incentives for domestic R&D and manufacturing scale-up.
Significance and Way Forward
- Strengthen regulatory harmonization: Establish a centralized biosimilar approval authority to streamline processes, reduce duplication, and align standards with global best practices.
- Enhance reimbursement frameworks: Integrate biosimilars into public health insurance schemes and government procurement to increase accessibility.
- Promote awareness campaigns: Educate healthcare providers and patients on biosimilar efficacy and safety to boost confidence and adoption.
- Support R&D investment: Expand funding beyond the DBT’s Biopharma Mission to incentivize innovation and scale manufacturing capabilities.
- Leverage international approvals: Use approvals like Health Canada’s NOC as benchmarks to attract global partnerships and exports.
- Biosimilars are approved under the New Drugs and Clinical Trials Rules, 2019.
- Approval of biosimilars requires demonstration of identical molecular structure to the reference biologic.
- Section 3(d) of the Patents Act, 1970, restricts patentability of new forms of known substances unless enhanced efficacy is shown.
Which of the above statements is/are correct?
- The global biosimilars market was valued at USD 17.5 billion in 2023 and is expected to grow at a CAGR of 20% until 2030.
- India’s biosimilar market is projected to reach USD 3 billion by 2025 with a CAGR of 25%.
- European Medicines Agency (EMA) has approved over 60 biosimilars since 2015, contributing to a 40% reduction in biologic drug costs across member states.
Which of the above statements is/are correct?
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 (Science & Technology), Paper 3 (Economic Development)
- Jharkhand Angle: Jharkhand hosts biotechnology clusters and pharmaceutical manufacturing units; improved biosimilar policies can boost local employment and healthcare affordability.
- Mains Pointer: Frame answers linking national biosimilar policies with state-level industrial growth and public health benefits in Jharkhand.
What is a biosimilar drug?
A biosimilar is a biologic medical product highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, and potency. Unlike generics, biosimilars are complex molecules derived from living organisms.
How does the New Drugs and Clinical Trials Rules, 2019 regulate biosimilars in India?
These rules require biosimilar applicants to demonstrate similarity in quality, safety, and efficacy to the reference biologic through analytical, preclinical, and clinical studies before approval by CDSCO.
What role does Section 3(d) of the Patents Act play in biosimilar development?
Section 3(d) prevents patenting of new forms of known substances without enhanced efficacy, limiting evergreening and facilitating earlier market entry of biosimilars after patent expiry of originator biologics.
Why is Health Canada’s NOC significant for Aurobindo Pharma?
The NOC certifies that Aurobindo’s biosimilar meets Canadian regulatory standards, enabling access to a lucrative oncology biosimilar market and validating India’s manufacturing and regulatory capabilities internationally.
What are the main challenges limiting biosimilar uptake in India?
Challenges include fragmented regulatory processes, limited reimbursement policies, low public and physician awareness, patent litigation risks, and underdeveloped post-marketing surveillance.